Molecular Signatures for Diagnosing Scleroderma
The present invention features methods for classifying, determining severity, and predicting clinical endpoints of scleroderma based upon the expression of selected biomarker genes.
Attached files:Patents:WO 2,010,008,543
Inventor(s):
WHITFIELD MICHAEL L [US]; SARGENT JENNIFER L [US]; PENDERGRASS SARAH A [US]; MILANO AUSRA [US]
Type of Offer:
Licensing
« More Biotech Patents